Clinical trial · Observational
Prospective Trial for the Evaluation of Radiogenomics in Advanced Rectal Cancer
Prospective Clinical Trial for the Evaluation of Radiogenomics: Correlation, Treatment Response and Prognosis in Patients With Advanced Rectal Cancer, Who Undergo Preoperative Chemoradiation
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In patients with advanced rectal cancer, molecular subtypes will be identified by preoperative biopsy, CT, MRI / PET radiomics analysis, clinical features, and clinical features will be confirmed and compared. Also, we want to confirm the relationship between these factors and the treatment response after chemoradiotherapy before surgery. The prognosis will be then assessed through 5-year overall survival and 3-year disease free survival. A prospective clinical trial, recruiting 210 persons (approximately 53 per year) that meet the selection criteria for approximately four years from the IRB approval date in 2019 (about 53 per year) We will analyze the data and then collect and analyze the data and report the results.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Rectal Cancer | Malignant Rectal Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- K-RAS Mutation
- timeFrame
- 4 weeks
- description
- K-RAS Mutation status
Secondary outcomes (1)
- measure
- Radiomics - MR image findings
- timeFrame
- 4 weeks
- description
- Radiologic features
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Age: 20-80 years * Patients diagnosed with mid-lower rectal cancer and expected to receive chemoradiotherapy before surgery Exclusion Criteria: * Patients with distal metastases confirmed at diagnosis * Patients with other bowel diseases such as IBD, ischemic colitis and TB colitis in addition to colorectal cancer * If patients do not agree with this study
References
Publications (0)
Data not yet available